First published 9/27/2026, 9:10:15 PM · Last updated 9/27/2026, 9:10:15 PM

NCCN Risk Groups Do Not Predict Adverse Pathology or Oncologic Outcomes Among Patients With Grade Group 1 Prostate Cancer in the MRI Era

A Wiley-published journal article examines whether NCCN risk groups predict adverse pathology or oncologic outcomes for patients with Grade Group 1 prostate cancer in the MRI era. The provided excerpt lists only the publisher and content type and includes no study methods, results, sample size, or location details.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

A peer-reviewed article addresses the predictive value of established risk groups for low-grade prostate cancer during the MRI era, which is relevant to clinical research and practice.

Sources

NCCN Risk Groups Do Not Predict Adverse Pathology or Oncologic Outcomes Among Patients With Grade Group 1 Prostate Cancer in the MRI Era

Report an issue